Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema

Abstract This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic mac...

Full description

Bibliographic Details
Main Authors: Takao Hirano, Yuichi Toriyama, Yoshihiro Takamura, Masahiko Sugimoto, Taiji Nagaoka, Yoshimi Sugiura, Fumiki Okamoto, Michiyuki Saito, Kousuke Noda, Shigeo Yoshida, Akihiro Ishibazawa, Osamu Sawada, Toshinori Murata
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-83811-y

Internet

https://doi.org/10.1038/s41598-021-83811-y

Similar Items